Related Experiment Video
Updated: Sep 11, 2025
09:08
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
6.8K
Bioinformatics Analysis Identifies Lipid Droplet-Associated Gene Signatures as Promising Prognostic and Diagnostic
Vijayalakshmi N Ayyagari1,2, Miao Li1, Paula Diaz-Sylvester1,2,3
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
Cancer Reports (Hoboken, N.J.)
|August 13, 2025
Summary
This study identifies novel gene signatures for endometrial cancer (EC) diagnosis and prognosis. Lipid droplet-associated genes (LDAGs) can predict patient survival and distinguish tumor from normal tissues, aiding early detection and personalized treatment.
Area of Science:
- Oncology
- Genomics
- Metabolomics
Background:
- Endometrial cancer (EC) diagnosis and prognosis require effective tools.
- Metabolic dysregulation is key in EC pathogenesis, but lipid droplet-associated genes (LDAGs) roles are understudied.
Purpose of the Study:
- To develop LDAG-based gene signatures for EC diagnosis and prognosis.
- To explore the clinical relevance of LDAGs in EC.
Main Methods:
- Systematic analysis of LDAGs in public EC datasets.
- Development of a four-gene prognostic model using LASSO and Cox regression.
- Construction of a six-gene diagnostic model using LASSO, ROC, and logistic regression.
- Validation using Kaplan-Meier, ROC, and SVM analyses.
Main Results:
- A four-gene prognostic model (LMLN, LMO3, PRKAA2, RAB10) significantly stratified EC patients by survival risk (p < 0.05, AUC > 0.70).
- A six-gene diagnostic model (AIFM2, ABCG1, LIPG, DGAT2, LPCAT1, VCP) achieved high accuracy in classifying tumor vs. normal tissues (AUC ≈ 0.99, 99.8% accuracy).
- Enrichment analyses linked DE-LDAGs to lipid metabolism, ER stress, cholesterol homeostasis, and autophagy.
Conclusions:
- This study establishes the first comprehensive LDAG signatures for EC prognosis and diagnosis.
- These signatures support a metabolism-driven EC classification framework.
- The findings suggest potential clinical utility for early detection, risk stratification, and personalized EC treatment.
